Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01087658
Other study ID # OXALI_L_03768
Secondary ID U1111-1116-9494
Status Completed
Phase Phase 3
First received March 15, 2010
Last updated June 20, 2013
Start date February 2010
Est. completion date March 2013

Study information

Verified date June 2013
Source Sanofi
Contact n/a
Is FDA regulated No
Health authority Canada: Health Canada
Study type Interventional

Clinical Trial Summary

Primary Objective:

To assess the benefit of glutamine when added to calcium-magnesium on the occurrence of grade 2, 3 and 4 peripheral sensory neuropathy (PSN) related to oxaliplatin with the National Cancer Institute-Common Terminology Criteria for Adverse Event (NCI-CTCAE) scale taking into account the time from start of oxaliplatin at which the first event occurred.

Secondary Objective:

To determine cumulative dose of oxaliplatin and time when the first occurrence of grade 2, 3 or 4 PSN.

To determine the incidence of dose-reductions, dose-delays and discontinuations of oxaliplatin due to PSN grade 3 or 4.

To assess effects of glutamine when added to calcium-magnesium on patients-reported outcomes using the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity 12 items questionnaire (FACT/GOG NTX-12) subscale.

To evaluate the incidence of diarrhea. To determine Progression Free Survival (PFS) in metastatic patients.


Recruitment information / eligibility

Status Completed
Enrollment 200
Est. completion date March 2013
Est. primary completion date March 2013
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion criteria:

1. Histologically- or cytologically- proven adenocarcinoma of the colon or rectum.

2. Disease either in adjuvant or 1st line metastatic setting.

3. Eastern Cooperation Oncology Group (ECOG) performance status inferior or equal to 2.

4. At least 4 weeks following any major surgical procedure(s) and recovery from any surgical sequelae.

5. Electrocardiogram (ECG) with no acute or recent changes within limit of normal range, and not presenting abnormalities contraindicating the proposed chemotherapy.

6. Adequate liver and kidney function:

- Total bilirubin inferior to 1.5 ULN

- Serum creatinine inferior to 150 umol/L

- Creatinine clearance (ClCr) superior to 45 mL/min

- ALT/AST inferior to 3 ULN

- Alkaline phosphatase inferior or equal to 2 ULN, unless liver metastases are present and documented at baseline by Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) scans (inferior or equal to 3,5 ULN in that case).

7. Adequate hematological function:

- Neutrophils superior or equal to 1.5 x 109/L

- Platelet count superior or equal to 100 x 109/L

- Hemoglobin superior to 9 g/dL

Exclusion criteria:

1. Any condition or past medical history that contra-indicates treatment with oxaliplatin, 5-fluorouracil (5-FU), leucovorin (LV) or capecitabine as reported in the approved labeling information.

2. Previous oxaliplatin-based chemotherapy.

3. Previous or current diagnosis of PSN.

4. Concomitant treatments with drugs/ingredients reported to have a potential activity in preventing PSN: carbamazepine, amitriptyline, gabapentin, phenytoin, glutathione, alpha-lipoic acid, celecoxib, amifostine, venlafaxine, vitamin B1 (thiamine), B6 (pyridoxine).

5. History of known allergy to oxaliplatin or other platinum agents, 5-FU, LV or capecitabine.

6. History of known allergy to glutamine or to calcium-magnesium.

7. Participation in another clinical trial with any investigational drug within 30 days prior to study screening.

8. Uncontrolled intercurrent illness: e.g. high blood pressure, unstable angina, symptomatic congestive heart failure (New York Heart Association Classification III or IV),

9. Serious cardiac arrhythmia, diabetes, or active infection.

10. Concurrent active cancer originating from a primary site other than colon or rectum.

11. Presence of any symptom suggesting brain metastasis.

12. Patients who are pregnant or breast-feeding

13. Patients (males and females) with reproductive potential not implementing accepted and effective method of contraception

14. For patient who will receive Bevacizumab: Bevacizumab is contraindicated in patients with known hypersensitivity to any components of the product to Chinese hamster ovary cell product or other recombinant human or humanized antibodies

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Glutamine
Per os
Calcium and Magnesium
Intravenous

Locations

Country Name City State
Canada Investigational Site Number 0001 Greenfield Park
Canada Investigational Site Number 124-005 Laval
Canada Investigational Site Number 124-007 London
Canada Investigational Site Number 124-014 Moncton
Canada Investigational Site Number 124-004 Montreal
Canada Investigational Site Number 124-006 Montreal
Canada Investigational Site Number 124-011 Montreal
Canada Investigational Site Number 124010 Montreal
Canada Investigational Site Number 124-015 Oshawa
Canada Investigational Site Number 124-012 Ottawa
Canada Investigational Site Number 124-003 Quebec
Canada Investigational Site Number 124-017 Rimouski
Canada Investigational Site Number 124-002 Toronto
Canada Investigational Site Number 124-016 Winnipeg

Sponsors (1)

Lead Sponsor Collaborator
Sanofi

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Occurence of peripheral sensory neuropathy (PSN) grade 2, 3 and 4 assessed by the National Cancer Institute Common Terminology Criteria for Adverse Event (NCI-CTCAE) Every cycle i.e. 2 or 3 weeks according to the treatment arm No
Secondary Cumulative dose of oxaliplatin and time of onset when the first PSN grade 2, 3 or 4 occurs Every cycle i.e. 2 or 3 weeks according to the treatment arm No
Secondary Dose-reduction, dose-delay and discontinuation of oxaliplatin due to PSN grade 3 or 4 Every cycle i.e. 2 or 3 weeks according to the treatment arm No
Secondary Patient self-reported neurotoxicity scale for chronic peripheral neuropathy Every cycle i.e. 2 or 3 weeks according to the treatment arm No
Secondary Progression Free Survival / PFS (for metastatic patients) Every cycle i.e. 2 or 3 weeks according to the treatment arm No
See also
  Status Clinical Trial Phase
Recruiting NCT04552093 - Hepatic Arterial Infusion Pump Chemotherapy Combined With Systemic Chemotherapy (PUMP-IT) Phase 2/Phase 3
Completed NCT04192565 - A Prospective Investigation of the ColubrisMX ELS System N/A
Completed NCT05178745 - A Prospective Observational Cohort Study Evaluating Resection Rate in Patients With Metastatic Colorectal Cancer Treated With Aflibercept in Combination With FOLFIRI - Observatoire résection
Recruiting NCT03561350 - Detect Microsatellite Instability Status in Blood Sample of Advanced Colorectal Cancer Patients by Next-Generation Sequencing
Recruiting NCT06128798 - Effect of Preoperative Immunonutrition Versus Standard Oral Nutrition in Patient Undergoing Colorectal Surgery. N/A
Recruiting NCT03602677 - Indocyanine Green Fluorescence Imaging in Prevention of Colorectal Anastomotic Leakage N/A
Completed NCT03631407 - Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC) (MK-7690-046) Phase 2
Withdrawn NCT04192929 - Chromoendoscopy or Narrow Band Imaging (NBI) for Improving Adenoma Detection in Colonoscopy N/A
Recruiting NCT03042091 - Neomycin and Metronidazole Hydrochloride With or Without Polyethylene Glycol in Reducing Infection in Patients Undergoing Elective Colorectal Surgery Early Phase 1
Completed NCT02889679 - Underwater Resection of Non-pedunculated Colorectal Lesions N/A
Terminated NCT02842580 - De-escalation Chemotherapies Versus Escalation in Non Pre-treated Unresectable Patients With Metastatic Colorectal Cancer Phase 2
Completed NCT02564835 - Effects of Yoga on Cognitive and Immune Function in Colorectal Cancer N/A
Completed NCT02503696 - Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD) N/A
Completed NCT02149108 - Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1) Phase 3
Completed NCT02599103 - The Effects of Various Cooking Oils on Health Related Biomarkers in Healthy Subjects N/A
Completed NCT01719926 - Phase I Platinum Based Chemotherapy Plus Indomethacin Phase 1
Completed NCT01669109 - Hatha Yoga for Patients With Colorectal Cancer N/A
Recruiting NCT01428752 - Study of Prevalence of Colorectal Adenoma in 30- to 49-year-old Subjects With a Family History of Colorectal Cancer N/A
Completed NCT01978717 - General Anesthesia Combined With Epidural Anesthesia Mitigates the Surgical Stress-related Immunosuppression in Patients With Colorectal Cancer N/A
Completed NCT01877018 - Colorectal Cancer Screening in Primary Care N/A